drugset
drugset / Trial / NCT06908707

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

NCT06908707 ↗

Phase 1 Completed 32 enrolled Laekna Limited Eli Lilly and Company · collab
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women

Timeline

Start
2025-04-22
Primary completion
2025-10-23
Completion
2025-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject LAE102 Unknown — Subcutaneous

Indications

No indication recorded.